Carlotta Costa

This user account status is Approved

This user has not added any information to their profile yet.

Novartis Institute for Biomedical Research
PI3K, CDK4/6, ER
1-The Strategy of PIKing a Target: What Is AKTually Most Effective? Costa C, Bosch A. Clin Cancer Res. 2018 May 1;24(9):2029-2031. doi: 10.1158/1078-0432.CCR-17-3440 2-The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK. Sci Transl Med. 2017 May 24;9(391). pii: eaal4682. doi: 10.1126/scitranslmed.aal4682 3-Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Ham J, Costa C, Sano R, Lochmann TL, Sennott EM, Patel NU, Dastur A, Gomez-Caraballo M, Krytska K, Hata AN, Floros KV, Hughes MT, Jakubik CT, Heisey DA, Ferrell JT, Bristol ML, March RJ, Yates C, Hicks MA, Nakajima W, Gowda M, Windle BE, Dozmorov MG, Garnett MJ, McDermott U, Harada H, Taylor SM, Morgan IM, Benes CH, Engelman JA, Mossé YP, Faber AC. 4-Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B, Rikova K, Zhao J, Hirsch E, Benes CH, Engelman JA. 5-The double life of p85. Costa C, Engelman JA. Cancer Cell. 2014 Oct 13;26(4):445-7. doi: 10.1016/j.ccell.2014.09.011. 6-CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, Lehar J, Wiesmann M, Wartmann M, Chen Y, Cao ZA, Pinzon-Ortiz M, Kim S, Schlegel R, Huang A, Engelman JA. Cancer Cell. 2014 Jul 14;26(1):136-49. doi: 10.1016/j.ccr.2014.05.020. 7-PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M, Benes CH, Engelman JA. roc Natl Acad Sci U S A. 2013 Dec 24;110(52):21124-9. doi: 10.1073/pnas.1314124110. 8-MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA. Cancer Res. 2012 Jul 1;72(13):3228-37. doi: 10.1158/0008-5472.CAN-11-3747